CancerNetwork® sat down with Richard D. Kim, MD, of the Moffitt Cancer Center at the 2021 ASCO Annual Meeting to talk about the many ways oncologists can approach treating hepatocellular carcinoma with combination regimens.
At ASCO 2021, Tanios S. Bekaii-Saab, MD, talked about some of his research in patients with IDH1/2–positive cholangiocarcinoma presented at the meeting.
At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, to discuss recent updates in the treatment of gastrointestinal malignancies.
At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, about genomic drivers in cholangiocarcinoma.
Data from a phase 1b trial of the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma display safety and early efficacy.
Adding toripalimab and hepatic arterial infusion chemotherapy to lenvatinib yielded robust, durable responses for patients with advanced hepatocellular carcinoma.
Liposomal irinotecan (Onivyde) plus 5-fluorouracil/leucovorin (5-FU/LV) mproved progression-free survival (PFS) and overall survival (OS) in patients with metastatic biliary tract cancer whose disease had progressed after frontline gemcitabine/cisplatin.
Overall survival and progression-free survival was improved with frontline camrelizumab plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.
Survival outcomes improved when nivolumab was added to either ipilimumab or chemotherapy versus chemotherapy alone in advanced/metastatic esophageal squamous cell carcinoma
The professor from MD Anderson Cancer Center spoke about the exploration of different concepts for the treatment of gastrointestinal cancers.